TrialEuropean journal of clinical pharmacology2023

Results from a first-in-human study of dersimelagon, an investigational oral selective MC1R agonist.

Akihito Ogasawara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.